Madrigal Pharmaceuticals, Inc. (MDGL) financial statements (2020 and earlier)

Company profile

Business Address 200 BARR HARBOR DRIVE, SUITE 400
WEST CONSHOHOCKEN, PA 19428
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:43948419240679892
Cash and cash equivalents475714919354648
Short-term investments3924264321325243
Other undisclosed cash, cash equivalents, and short-term investments    000
Prepaid expense and other current assets1
Other undisclosed current assets110112(0)
Total current assets:44048519241689992
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment1000012
Other noncurrent assets     0 
Prepaid expense and other noncurrent assets1
Total noncurrent assets:2000013
TOTAL ASSETS:442485192416810195
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2581056910
Accounts payable1221137
Accrued liabilities2468422 
Employee-related liabilities    343
Debt0   599
Other undisclosed current liabilities    71213
Total current liabilities:258105183132
Noncurrent Liabilities
Long-term debt and lease obligation0    514
Long-term debt, excluding current maturities     514
Capital lease obligations    00
Operating lease, liability0
Total noncurrent liabilities:0    514
Total liabilities:258105183646
Stockholders' equity
Stockholders' equity attributable to parent41747718236506549
Common stock0000000
Additional paid in capital640617289112757703600
Accumulated other comprehensive income (loss)0(0)(0)0000
Accumulated deficit(223)(139)(106)(75)(706)(638)(551)
Total stockholders' equity:41747718236506549
TOTAL LIABILITIES AND EQUITY:442485192416810195

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit: 00    
Operating expenses(95)(41)(32)(25)(68)(84)(88)
Other undisclosed operating loss (0)(0)    
Operating loss:(95)(41)(32)(25)(68)(84)(88)
Interest and debt expense   (1)   
Loss before gain (loss) on sale of properties:(95)(41)(32)(26)(68)(84)(88)
Other undisclosed net income1181    
Net loss attributable to parent:(84)(33)(31)(26)(68)(84)(88)
Other undisclosed net income (loss) available to common stockholders, basic   0(1)(2)(3)
Net loss available to common stockholders, diluted:(84)(33)(31)(26)(69)(86)(90)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(84)(33)(31)(26)(68)(84)(88)
Comprehensive loss:(84)(33)(31)(26)(68)(84)(88)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1(0)(0)0(1)(2)(3)
Comprehensive loss, net of tax, attributable to parent:(83)(33)(31)(26)(69)(86)(90)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: